Why is Telix Pharmaceuticals stock surging today?

Telix Pharmaceuticals' stock surged 10.3% to A$18.03 on Tuesday following the U.S. FDA's approval of its cancer imaging drug, Pixclara (floretyrosine F 18). This approval marks a significant milestone for the company, as it establishes Telix as the sole holder of an FDA-approved radiopharmaceutical imaging agent for the treatment of recurrent or progressive glioma, a type of brain tumor that accounts for 30% of all brain and central nervous system tumors and 80% of malignant brain tumors.

The approval provides Telix with a strong commercial opportunity and was further bolstered by the company's senior leadership presenting at the H.C. Wainwright 28th Annual Global Investment Conference in New York, where they directly addressed institutional investors about the Pixclara approval and the company's broader pipeline.

Additionally, Telix reported strong financial performance in H1 2026, with revenue increasing by 22% year-over-year to US$477 million, and adjusted EBITDA surging by 146%. The company's guidance was also raised to exceed US$1 billion in total revenue and other income for the full year. These factors, combined with the approval of Pixclara and the company's visibility at a high-profile investor conference, have contributed to the surge in Telix Pharmaceuticals' stock price.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.